Steris Plc (STE) - Fiscal Year 2026 10-K Summary
Business Context and Reporting Period
Company: STERIS Plc
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended March 31, 2026
Business Overview: STERIS is a global provider of infection prevention products and services for healthcare, medical device, and pharmaceutical customers. The company operates three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Dental segment was divested in fiscal 2025 and is reported as discontinued operations.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 |
|---|---|---|
| Total Revenues | $5,935.9 million | $5,459.5 million |
| Net Income (Attributable to Shareholders) | $782.3 million | $614.6 million |
| Diluted EPS | $7.93 | $6.20 |
| Gross Profit Margin | 44.2% | 44.0% |
| Operating Income | $1,101.8 million | $866.6 million |
| Operating Margin | 18.6% | 15.9% |
| Free Cash Flow | $982.9 million | $787.2 million |
| Total Debt (Net of deferred fees) | $1,931.7 million | $2,043.7 million |
| Debt-to-Total Capital Ratio | 21.3% | 23.6% |
| Cash and Cash Equivalents | $439.6 million | $171.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8.7% year-over-year, driven by higher volume, pricing, and favorable foreign currency movements. Service revenues grew 11.1%, while consumable and capital equipment revenues grew 7.3% and 5.6%, respectively.
- Profitability Expansion: Operating income surged 27.1% to $1.1 billion. This was primarily due to pricing, volume growth, and significantly lower restructuring and litigation costs compared to fiscal 2025.
- Cost Reductions: Restructuring expenses dropped 91.1% to $4.1 million from $46.0 million in the prior year. The Illinois EO litigation settlement charge of $48.2 million recorded in fiscal 2025 did not recur in fiscal 2026.
- Cash Flow: Free cash flow increased 24.9% to $982.9 million, driven by improved net income despite a lower contribution from working capital.
- Divestiture Impact: The Dental segment was sold in fiscal 2025; historical data has been retrospectively adjusted to exclude this segment for comparability.
Guidance, Outlook, and Risks
Outlook: Management expects to continue managing costs, growing through internal product development, and investing in capacity and efficiency. The company plans to augment these efforts with potential acquisitions.
Shareholder Returns:
- Dividends: Quarterly dividend increased to $0.63 per share (total $2.46 per share for the year).
- Repurchases: A new $1.0 billion share repurchase program was authorized in May 2026, replacing the outgoing program which had $75.0 million remaining.
Key Risks and Contingencies:
- EO Litigation: A settlement agreement for up to $48.2 million regarding ethylene oxide (EO) exposure claims in Illinois was finalized in fiscal 2025. The claims process is ongoing, and the company retains "walkaway rights" if certain terms are not met.
- Regulatory Environment: The company faces extensive regulation from the FDA and global authorities. Changes in healthcare policy or reimbursement levels could impact demand.
- Taxation: The U.S. "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025. While it had no material impact on fiscal 2026, future guidance could affect tax rates. Additionally, global minimum tax (GloBE) rules may increase tax uncertainty.
- Supply Chain: Reliance on single-source suppliers for key materials like cobalt-60 and ethylene oxide poses supply chain risks.
Investor Verification Checklist
- EO Litigation Status: Verify the progress of the Illinois EO claims administration process and the likelihood of the company exercising walkaway rights.
- Segment Margins: Monitor the Healthcare segment's operating margin (24.6% in FY26), which declined slightly due to tariffs and inflation offsetting volume/pricing gains.
- Backlog Trends: Review the $490.7 million capital equipment backlog (up from $452.9 million) as an indicator of future revenue visibility.
- Acquisition Integration: Assess the integration of recent tuck-in acquisitions and the $134 million equity investment in a non-U.S. healthcare manufacturer.
- Tax Rate Volatility: Track the effective tax rate (25.0% in FY26) against the statutory rate, considering the impact of geographic income mix and discrete items.